Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
The dual-incretin behind Mounjaro and Zepbound — how it works, what the evidence shows, and why it belongs under a provider's care.
Tirzepatide is one of the most-studied and most-discussed metabolic medications of the decade. It's also frequently sold in gray-market forms that strip away the medical supervision it was designed to have. This page is the straight version: what it is, what the science says, and what responsible use looks like.
Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most earlier medications in this space — semaglutide among them — target GLP-1 alone. Tirzepatide's "dual agonist" design is what makes it pharmacologically distinct, and it's why it drew so much attention in trials.
It's approved by the FDA under two brand names: Mounjaro for type 2 diabetes, and Zepbound for chronic weight management in adults who meet specific clinical criteria. Both are prescription-only, and both are intended to be used alongside diet and physical activity — not as a replacement for them.
The two receptors it targets do complementary things in the body:
Together, these lower blood sugar and reduce food intake. The weekly dosing schedule exists because the molecule is engineered to stay active in the body far longer than natural incretin hormones, which last only minutes.
Tirzepatide's approvals rest on large randomized controlled trials — the SURPASS program in type 2 diabetes and the SURMOUNT program in weight management. Across those trials, participants saw meaningful average improvements in blood sugar control and substantial average weight reduction over the study periods, with effects scaling by dose.
Two honest caveats belong next to those results. First, the trials paired the medication with lifestyle intervention and close monitoring — the drug wasn't studied as a standalone shortcut. Second, when the medication is stopped, much of the weight effect tends to reverse over time unless other changes are sustained, which is why providers treat it as part of a longer plan rather than a quick cycle.
The most common side effects are gastrointestinal — nausea, diarrhea, reduced appetite, and constipation — and they're usually most noticeable when starting or increasing the dose. That gradual "titration" schedule exists specifically to manage them, which is one reason self-dosing gray-market product is risky.
Tirzepatide carries a boxed warning related to thyroid C-cell tumors seen in rodent studies, and it is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. It also requires caution with a history of pancreatitis, certain GI conditions, and in combination with some other medications. This is exactly the kind of screening a licensed provider does — and a website with an age checkbox does not.
Tirzepatide is a legitimate, FDA-approved medication with strong trial evidence behind its approved uses. It is also a prescription drug with real contraindications and a boxed warning — which is precisely why it should be evaluated, prescribed, and monitored by a licensed provider, and dispensed by a licensed pharmacy. The compound is the same either way; the safety comes from the supervision around it.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense tirzepatide or any medication.